This study aims to explore the compatibility relationships of Citri Reticulatae Pericarpium Viride-Aurantii Fructus drug pair(CV-AF) in the treatment of dyskinetic gastrointestinal diseases (GD) based on network pharmacology and animal experiments.The intersection targets between CV-AF and GD were used for the chart construction and enrichment analysis of protein-protein interactions;and the key targets of the top 5 betweenness centrality values in the “target-component-pathway” chart were selected for molecular docking with their corresponding components;the body weight,gastric residual rates,and serum motilin concentrations of mice were used as indicators to observe the differences between CV-AF (1∶1,1∶2,2∶1) and their corresponding single drug for the treatment of gastrointestinal dyskinesia in mice induced by L-arginine solution.The results of network pharmacology showed that the core targets of CV-AF for the treatment of GD were CYP2C9,EGFR,and HSD11B1;the core components were  β-sitosterol, sinensetin,naringenin,neohesperidin_qt,hesperetin,marmin,thymol,nobiletin,and 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl) chroman-4-one;the core targets were well combined with the core components.The results of animal experiments indicated that both individual and combined use of CV-AF ameliorated gastrointestinal dyskinesia of mice;the efficacy of CV-AF groups was better than their corresponding single drug groups,with the CV-AF 1∶2 group being better than the CV-AF 1∶1 group and the CV-AF 2∶1 group.This study reveals the optimal pairing ratio and action mechanism for the treatment of dyskinetic GD by CV-AF preliminary,which can provide a reference basis for further research on the treatment of GD by CV-AF.